Literature DB >> 18777592

Mucosal cytokine network in inflammatory bowel disease.

Akira Andoh1, Yuhki Yagi, Makoto Shioya, Atsushi Nishida, Tomoyuki Tsujikawa, Yoshihide Fujiyama.   

Abstract

Inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn's disease (CD) are characterized by ongoing mucosal inflammation in which dysfunction of the host immunologic response against dietary factors and commensal bacteria is involved. The chronic inflammatory process leads to disruption of the epithelial barrier, and the formation of epithelial ulceration. This permits easy access for the luminal microbiota and dietary antigens to cells resident in the lamina propria, and stimulates further pathological immune cell responses. Cytokines are essential mediators of the interactions between activated immune cells and non-immune cells, including epithelial and mesenchymal cells. The clinical efficacy of targeting TNF-alpha clearly indicates that cytokines are the therapeutic targets in IBD patients. In this manuscript, we focus on the biological activities of recently-reported cytokines [Interleukin (IL)-17 cytokine family, IL-31 and IL-32], which might play a role through interaction with TNF-alpha in the pathophysiology of IBD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18777592      PMCID: PMC2744005          DOI: 10.3748/wjg.14.5154

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  74 in total

Review 1.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

Review 2.  Th17: the third member of the effector T cell trilogy.

Authors:  Estelle Bettelli; Thomas Korn; Vijay K Kuchroo
Journal:  Curr Opin Immunol       Date:  2007-09-04       Impact factor: 7.486

3.  IL-17 stimulates inflammatory responses via NF-kappaB and MAP kinase pathways in human colonic myofibroblasts.

Authors:  Kazunori Hata; Akira Andoh; Mitsue Shimada; Sanae Fujino; Shigeki Bamba; Yoshio Araki; Takafumi Okuno; Yoshihide Fujiyama; Tadao Bamba
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2002-06       Impact factor: 4.052

4.  The interleukin-10 family of cytokines.

Authors:  Helmut Fickenscher; Simon Hör; Heide Küpers; Andrea Knappe; Sabine Wittmann; Heinrich Sticht
Journal:  Trends Immunol       Date:  2002-02       Impact factor: 16.687

5.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease.

Authors:  J P Hugot; M Chamaillard; H Zouali; S Lesage; J P Cézard; J Belaiche; S Almer; C Tysk; C A O'Morain; M Gassull; V Binder; Y Finkel; A Cortot; R Modigliani; P Laurent-Puig; C Gower-Rousseau; J Macry; J F Colombel; M Sahbatou; G Thomas
Journal:  Nature       Date:  2001-05-31       Impact factor: 49.962

6.  IL-6 secretion by human pancreatic periacinar myofibroblasts in response to inflammatory mediators.

Authors:  Mitsue Shimada; Akira Andoh; Kazunori Hata; Kazuhito Tasaki; Yoshio Araki; Yoshihide Fujiyama; Tadao Bamba
Journal:  J Immunol       Date:  2002-01-15       Impact factor: 5.422

7.  A novel type I cytokine receptor is expressed on monocytes, signals proliferation, and activates STAT-3 and STAT-5.

Authors:  Nico Ghilardi; Ji Li; Jo-Anne Hongo; Sothy Yi; Austin Gurney; Frederic J de Sauvage
Journal:  J Biol Chem       Date:  2002-03-04       Impact factor: 5.157

Review 8.  Crohn's disease: a review of current treatment with a focus on biologics.

Authors:  Julián Panés; Fernando Gomollón; Carlos Taxonera; Joaquin Hinojosa; Juan Clofent; Pilar Nos
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Interleukin-31 induces cytokine and chemokine production from human bronchial epithelial cells through activation of mitogen-activated protein kinase signalling pathways: implications for the allergic response.

Authors:  Wai K Ip; Chun K Wong; Mandy L Y Li; Pok W Li; Phyllis F Y Cheung; Christopher W K Lam
Journal:  Immunology       Date:  2007-07-11       Impact factor: 7.397

10.  Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis.

Authors:  G G Kaplan; C Hur; J Korzenik; B E Sands
Journal:  Aliment Pharmacol Ther       Date:  2007-10-11       Impact factor: 8.171

View more
  41 in total

Review 1.  [Chronic inflammatory intestinal diseases. Pathophysiology and therapy].

Authors:  K Herrlinger; B Wittig; E F Stange
Journal:  Internist (Berl)       Date:  2009-10       Impact factor: 0.743

Review 2.  From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease.

Authors:  Charles W Randall; John A Vizuete; Nicholas Martinez; John J Alvarez; Karthik V Garapati; Mazyar Malakouti; Carlo M Taboada
Journal:  Therap Adv Gastroenterol       Date:  2015-05       Impact factor: 4.409

3.  Soluble interleukin-6 receptor is elevated during influenza A virus infection and mediates the IL-6 and IL-32 inflammatory cytokine burst.

Authors:  Jun Wang; Qing Wang; Tao Han; Yong-Kui Li; Sheng-Li Zhu; Fang Ao; Jian Feng; Ming-Zhen Jing; Li Wang; Lin-Bai Ye; Ying Zhu
Journal:  Cell Mol Immunol       Date:  2014-09-01       Impact factor: 11.530

4.  Par-3 modulates intestinal epithelial barrier function through regulating intracellular trafficking of occludin and myosin light chain phosphorylation.

Authors:  Min Yu; Songwei Yang; Yuan Qiu; Guoqing Chen; Wensheng Wang; Chao Xu; Wenqiang Cai; Lihua Sun; Weidong Xiao; Hua Yang
Journal:  J Gastroenterol       Date:  2015-03-28       Impact factor: 7.527

5.  The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease.

Authors:  T Sugihara; A Kobori; H Imaeda; T Tsujikawa; K Amagase; K Takeuchi; Y Fujiyama; A Andoh
Journal:  Clin Exp Immunol       Date:  2010-01-19       Impact factor: 4.330

Review 6.  Molecular modulation of intestinal epithelial barrier: contribution of microbiota.

Authors:  Renu Sharma; Christopher Young; Josef Neu
Journal:  J Biomed Biotechnol       Date:  2010-01-31

7.  The inflammatory cytokine tumor necrosis factor modulates the expression of Salmonella typhimurium effector proteins.

Authors:  Jun Ma; Yong-Guo Zhang; Yinglin Xia; Jun Sun
Journal:  J Inflamm (Lond)       Date:  2010-08-12       Impact factor: 4.981

8.  Attenuation of TNF-driven murine ileitis by intestinal expression of the viral immunomodulator CrmD.

Authors:  A Viejo-Borbolla; A P Martin; L R Muniz; L Shang; F Marchesi; N Thirunarayanan; N Harpaz; R A Garcia; M Apostolaki; G C Furtado; L Mayer; G Kollias; A Alcami; S A Lira
Journal:  Mucosal Immunol       Date:  2010-07-21       Impact factor: 7.313

9.  Correlation of IL-31 gene polymorphisms with susceptibility and clinical recurrence of bladder cancer.

Authors:  Qin Li; Tielong Tang; Peng Zhang; Chenlu Liu; Yan Pu; Yan Zhang; Huizi Song; Yanyun Wang; Yaping Song; Min Su; Bin Zhou; Lin Zhang
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

10.  Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease.

Authors:  Nicola Eastaff-Leung; Nicholas Mabarrack; Angela Barbour; Adrian Cummins; Simon Barry
Journal:  J Clin Immunol       Date:  2010-01       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.